Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/salbutamol - Avillion/Pearl Therapeutics

Next Previous
Drug Profile

Budesonide/salbutamol - Avillion/Pearl Therapeutics

Alternative Names: AIRSUPRA; Albuterol/budesonide - Avillion/Pearl Therapeutics; BDA MDI/PT027; PT-027

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Avillion
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Pregnenediones; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 19 May 2025 Adverse events and efficacy data from the phase IIIb BATURA trial in Asthma released by Avillion
  • 18 Nov 2024 AstraZeneca completes a phase III trial for Asthma (PO) in USA (NCT05555290)
  • 24 Oct 2024 Efficacy and adverse events data from a phase IIIb BATURA trial in Asthma presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology(ACAAI-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top